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Abstract
Background: Long-acting injectable (LAI) formulations are not widely used in routine practice even though they
offer advantages in terms of relapse prevention. As part of a process to improve the quality of care, the French
Association for Biological Psychiatry and Neuropsychopharmacology (AFPBN) elaborated guidelines for the use and
management of antipsychotic depots in clinical practice.
Methods: Based on a literature review, a written survey was prepared that asked about 539 options in 32 specific
clinical situations concerning 3 fields: target-population, prescription and use, and specific populations. We
contacted 53 national experts, 42 of whom (79%) completed the survey. The options were scored using a 9-point
scale derived from the Rand Corporation and the University of California in the USA. According to the answers, a
categorical rank (first-line/preferred choice, second-line/alternate choice, third-line/usually inappropriate) was
assigned to each option. The first-line option was defined as a strategy rated as 7–9 (extremely appropriate) by at
least 50% of the experts. The following results summarize the key recommendations from the guidelines after data
analysis and interpretation of the results of the survey by the scientific committee.
Results: LAI antipsychotics are indicated in patients with schizophrenia, schizoaffective disorder, delusional disorder
and bipolar disorder. LAI second-generation antipsychotics are recommended as maintenance treatment after the
first episode of schizophrenia. LAI first-generation antipsychotics are not recommended in the early course of
schizophrenia and are not usually appropriate in bipolar disorder. LAI antipsychotics have long been viewed as a
treatment that should only be used for a small subgroup of patients with non-compliance, frequent relapses or
who pose a risk to others. The panel considers that LAI antipsychotics should be considered and systematically
proposed to any patients for whom maintenance antipsychotic treatment is indicated. Recommendations for medication
management when switching oral antipsychotics to LAI antipsychotics are proposed. Recommendations are also given
for the use of LAI in specific populations.
Conclusion: In an evidence-based clinical approach, psychiatrists, through shared decision-making, should be
systematically offering to most patients that require long-term antipsychotic treatment an LAI antipsychotic as a
first-line treatment.
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Treatment
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Background
Schizophrenia and bipolar disorder are examples of
some chronic illnesses for which there exists a high risk
of relapse associated with major functional conse-
quences. The pharmacologic strategy can be considered
as the cornerstone of the treatment for these patients.
Compliance is often mediocre with deleterious conse-
quences [1]. For example, the majority of patients with
schizophrenia (84%) discontinue their index anti-
psychotic during the follow-up period [2] and in the
long-term perspective, 40 to 50% seem to be non-
compliant [3], with no real difference in terms of adher-
ence between first-generation antipsychotics (FGA) and
second-generation antipsychotics (SGA) [4].
Long-acting injectable (LAI) antipsychotics have been
part of the pharmacopoeia for over 40 years. Various
meta-analyses highlight their interest as a relapse pre-
vention strategy in schizophrenia [5-7]. With regards to
non-adherence, most of the guidelines and algorithms
(except PORT 2009) state that depot antipsychotics are
an effective approach [8-10], with some guidelines actu-
ally recommending that switching the antipsychotic
formulation from oral to depot should be considered in
maintenance treatment [11].
Nevertheless, depot formulations are still poorly used
overall in routine practice, with prescription rates in dif-
ferent countries generally no more than 25% [12,13].
However, use of the depot forms varies between coun-
tries. Prescription rates are higher in France (23.5%) [14]
and the United Kingdom (29%) [12] compared to other
European countries. Several factors that deter psychia-
trists from using depot forms have been identified, stem-
ming from mistaken beliefs about good adherence,
patient refusal, perceived coercion or a presumed risk of
lower tolerance [13,15]. At a practical level, psychiatrists
need to be confident and competent in presenting pa-
tients with sufficient information to enable them to
make an informed choice about whether to accept oral
or LAI medication or neither. We state that the develop-
ment and diffusion of specific guidelines, addressing all
the aspects of the use of LAI antipsychotics, will in-
crease clinicians’ perceived competence. It will also help
to increase the percentage of patients to whom LAI
antipsychotics will be offered by psychiatrists as a
therapeutic option.
The objective of these guidelines is to propose a pre-
scription framework to clinicians for the use of a specific
formulation of antipsychotics (LAI) in diverse thera-
peutic indications and specific clinical situations. The
aim is to allow clinicians to offer the most appropriate
pharmaceutical strategies to the patients and to facilitate
the use of LAI antipsychotics in clinical practice. The rec-
ommendations presented here from a consensus-based
guidelines methodology (Formal Consensus Guidelines) are
based on scientific data and the consensus of a panel of
experts.
Methods
Questionnaire development
Initially, we performed an analysis and a literature re-
view concerning the indications and the use of LAI
antipsychotics. A literature search using the keywords
“antipsychotic”, “neuroleptic”, “first-generation anti-
psychotic”, “atypical antipsychotic”, “second-generation
antipsychotic”, “long-acting injectable”, “depot”, “depot
neuroleptic” was performed in PubMed and EMBASE
to find all the relevant studies published. Additional refer-
ences were identified from http://www.fda.gov and http://
www.ema.europa.eu.
Data from all of these sources was discussed and an
overview of the current evidence has been graded and
summarized using the French National Authority for
Health (HAS) “levels of evidence” criteria [16].
Following this first step, the scientific committee
(PML, LS, MA, PC, SG, SL) created a questionnaire con-
sisting of 32 questions that covered 539 therapeutic op-
tions. The 32 questions were regrouped into 3 areas that
were judged as essential:
– Target-population: Description of the different
indications of the LAI antipsychotics and of the
most appropriate period of the illness to introduce
the treatment.
– Prescription and use: Choice of the molecule,
methods of introduction, specific strategies
depending on the psychiatric disorder or co-
morbidities, and treatment monitoring.
– Specific population: Use of LAI antipsychotics in
pregnant women, elderly patients, subjects in a
precarious situation, and subjects having to be
treated in a prison establishment.
This questionnaire was designed to be completed by
an experts’ panel. The time required for its administra-
tion was estimated at around 3 hours.
At the time of development, all the LAI antipsy-
chotics available in France were proposed as thera-
peutic options (Table 1). They were regrouped into 2
categories:
– Long-acting injectable first-generation antipsychotics
(LAI FGA).
– Long-acting injectable second-generation antipsy-
chotics (LAI SGA).
This artificial separation FGA/SGA is not consen-
sual due to their heterogeneous profiles of efficacy
Llorca et al. BMC Psychiatry 2013, 13:340 Page 2 of 17
http://www.biomedcentral.com/1471-244X/13/340
and tolerability (especially for SGA) [17,18]. However,
we maintained both these categories to facilitate the
elaboration, the reading and the understanding of this
guideline.
Rating scale
The experts were able to express their level of agreement
or disagreement for each question. The rules that de-
scribe, on the one hand the agreement (or the disagree-
ment), and on the other hand the degree of convergence
of the expert opinions, were predefined.
Each expert answered each question with the help
of a graduated scale from 0 to 9 (0 meaning a “total
disagreement” or “a formal contraindication” and 9 in-
dicating a “total agreement” or “a formal indication”)
(Figure 1).
This scale is derived from a variation of the “Nominal
Group” method, developed by the Rand Corporation and
the University of California in the USA (“RAND/UCLA
appropriateness rating method”).
The scale has the advantage of being well stan-
dardized, used in medicine and of having been pub-
lished [19].
Expert selection
The Scientific Committee (Appendix 1) selected 53
French psychiatrists considered to be experts in the use
of LAI antipsychotics.
The selection criteria were:
– Clinical activity in the field of schizophrenia or
bipolar disorder.
– Publication (s) or communication (s) of research
work in the field of LAI antipsychotics in national or
international congresses.
Each expert was consulted individually for his or her
expertise using the supplied questionnaire. A follow-
up was established to ensure, essentially, the sending
and returning of these documents. A reminder of the
expert's mission was made. Written commitment from
each expert was requested. The experts participating in
this project were not paid.
Data analysis
The answers to each question or proposition were
quantitatively analyzed (number of answers, median,
mean, standard deviation, minimum, maximum)
(Table 2).
– First-line treatment/strategy was defined if at least
50% of the answers to the question were in the zone
7–9 and less than 20% were in the zone 0. The
treatment/strategy of choice was kept if at least 50%
of the experts had rated it 9.
– Second-line treatment/strategy was defined if less
than 50% of the answers to the question were in the
zone 7–9, at least 50% were in the cumulated zones
7–9 and 4–6, and less than 20% were in the zone 0.
– Third-line treatment/strategy was defined if less
than 50% of the answers to the question were in the
Table 1 LAI antipsychotics available in France (when the
survey was completed)
LAI second-generation
antipsychotics
Risperidone microsphere
Olanzapine pamoate
LAI first-generation antipsychotics Haloperidol decanoate
Zuclopenthixol decanoate
Flupentixol decanoate
Fluphenazine decanoate
Pipotiazine palmitate
Note: as paliperidone palmitate had a marketing authorization date after the
development of these guidelines, it could not be taken into account.
Figure 1 Rating scale.
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cumulated zones 7–9 and 4–6, and less than 20%
were in the zone 0.
– Contraindication was defined if at least 50% of the
answers were in the zone 0.
For all other cases the question was considered as
non-consensual. An example is given in Figure 2. The
results were interpreted by the scientific committee and
permitted the development of the recommendations. An
independent committee (Appendix 1) validated the final
version of recommendations (EH, CL, PT). Two mem-
bers of the scientific committee elaborated the final
document (LS, PML).
Results
The following sections summarize the key recommenda-
tions from the guidelines after data analysis and inter-
pretation of the results of the survey by the scientific
committee. The complete database (with questions and
answers) is available on the website www.afpbn.org.
However, several examples of questions, with the ex-
perts’ answers, are presented here to facilitate under-
standing of the results section.
Description of the expert population
Forty-two experts completed the questionnaire (Appendix 2),
representing 79% of those contacted. The reasons for the
non-participation of the remaining 11 experts were that
they had either too much consultancy work or insufficient
availability to reply within the time limits. The socio-
demographic data and professional activities of the experts’
panel are presented in Table 3.
Target population
Indications
Indications for the use of LAI FGA and LAI SGA are
summarized in Table 4.
The relevant question from the survey with the ex-
perts’ answers are given in Figure 2.
Table 2 Data analysis
Percentage of answers in the
zones
0 1-3 4-6 7-9
< 20% - < 50% ≥ 50% → First-line treatment/strategy
< 20% < 50% ≥ 50% and <
100%
→ Second-line treatment/strategy
< 20% - < 50% → Third-line treatment/strategy
≥ 50% - - - → Contraindication
For all other cases (−), the question was considered as non-consensual.
The following rules were used to conclude the analyzed therapeutic strategy.
Figure 2 Graphic results of the question about indications for use of LAI.
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LAI SGA are recommended (in monotherapy or
combination):
– as 1st line treatment in schizophrenia, delusional
disorder and schizoaffective disorder.
– as 2nd line treatment in bipolar disorder and
personality disorders.
They are contraindicated in organic mental disorders
with behavioural disorders (Alzheimer’s disease, vascular
dementia).
LAI FGA are recommended (in monotherapy or
combination):
– as 2nd line treatment in schizophrenia, delusional
disorder, schizoaffective disorder and personality
disorders.
They are contraindicated in recurrent depressive
disorder and in organic mental disorders with
behavioural disorders.
Most appropriate introduction period during the illness
The most appropriate period for the introduction of LAI
FGA and SGA are summarized Table 5.
Only LAI SGA are considered as a therapeutic option
during the initial phase of schizophrenic illness:
– They are recommended from the first psychotic
episode.
– Their introduction from the first recurrent psychotic
episode is also recommended (if the patient was not
treated with an LAI antipsychotic).
LAI FGA are not recommended during the early course
of schizophrenia (i.e. in a patient who has been newly diag-
nosed with schizophrenia and who has had no previous
antipsychotic treatment). They must be used as mainten-
ance treatment during the long-term evolution of the illness
in the case of efficacy of the corresponding oral formulation
and when the benefit/risk ratio is considered as satisfactory.
Choice criteria for an LAI FGA or LAI SGA according to the
clinical characteristics of patient
The different clinical criteria for the use of LAI FGA
and SGA are presented in Table 6.
Table 3 Socio-demographic data and professional
activities of the experts’ panel (N = 42 experts)
Age (years) N 42
Mean ± SD 46.81 ± 9.82
Min; Max 31; 63
Median 46
Years of practice N 41
Mean ± SD 17.29 ± 10.20
Min; Max 2; 37
Median 16
Treatment of patients in
outpatients
N 41
Mean ± SD 68.90 ± 22.43
Min; Max 25; 100
Median 75
Treatment of patients
in hospital
N 41
Mean ± SD 31.10 ± 22.43
Min; Max 0; 75
Median 25
During the last 5 years, in the
field of LAI FGA/LAI SGA
N 42
Clinical activity 42 (100.0%)
Research
projects
18 (42.9%)
Publications 12 (28.6%)
Communications N 36
Conferences 22 (61.1%)
Congress 24 (66.7%)
Teaching 22 (61.1%)
Table 4 LAI FGA and LAI SGA indications according to the
DSM-IV-TR criteria
LAI FGA LAI SGA
1st line treatment
Schizophrenia
Delusional disorder
Schizoaffective disorder
2nd line treatment
Schizophrenia Bipolar disorder
Delusional disorder Personality disorder
Schizoaffective disorder
Personality disorder
Table 5 Use of LAI FGA and LAI SGA according to the
period of the illness
LAI FGA LAI SGA
Schizophrenia
LAI FGA are not recommended in
the initial phase of the disorder.
Very early introduction of LAI SGA
is recommended (eventually from
the 1st psychotic episode).
LAI FGA can be used during the
maintenance treatment in the
case of the efficacy of the oral
form and when the benefit/risk
ratio is considered as satisfactory.
It is recommended that an LAI SGA
be introduced from the 1st
recurrent psychotic episode (if the
patient was not treated with an LAI
antipsychotic).
Bipolar disorder
LAI FGA are not recommended. LAI SGA are not recommended in
the initial phase of bipolar disorder.
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Schizophrenia
The preferential choice criteria for an LAI formulation
(as 1st line treatment) in patients with schizophrenia
are:
– Patients presenting frequent relapses, poor adherence
or non-acceptance of a long-term treatment.
LAI FGA or LAI SGA are recommended as 1st line
treatment. In the case of poor observance, LAI SGA are
considered as the treatment of choice.
– Patients presenting dangerous behavior.
LAI FGA and LAI SGA are recommended as 1st line
treatment.
– Patients presenting a low level of insight about
illness and need for treatment.
LAI FGA and LAI SGA are recommended as 1st line
treatment.
– Patients wishing treatment by LAI antipsychotic
and/or having a history of effective treatment by
LAI FGA or LAI SGA.
LAI FGA or LAI SGA are recommended as 1st line
treatment.
– Patients presenting cognitive impairment with an
impact on their functioning.
LAI SGA are recommended as 1st line treatment. LAI
FGA are not recommended.
– Socially and family isolated patients.
LAI SGA as 1st line treatment (LAI FGA as a 2nd line
treatment) are recommended for patients with poor so-
cial and family support.
– Patients receiving outpatient care without consent.
When a compulsory outpatient care program is planned,
LAI SGA as 1st line treatment (LAI FGA as 2nd line treat-
ment) are recommended.
The experts failed to reach a favorable consensus for the
preferential use of an LAI formulation (as 1st line treat-
ment) for the following groups. They just specified the pref-
erential category of LAI (FGA or SGA) for these groups.
– Patients presenting a predominant clinical
dimension.
The prevalence of positive or negative symptoms is not
a specific factor in choosing to use a depot treatment.
If a depot treatment is chosen:
* LAI SGA and LAI FGA are recommended (as 2nd
line treatment) for clinical forms where positive symp-
toms prevail.
* Only LAI SGA are recommended (as 2nd line treat-
ment) in cases of predominant negative symptoms.
– Patients presenting a high level of suicide intention.
Only LAI SGA are considered (as 2nd line treatment)
for patients presenting suicidal behavior during acute
episodes.
– Patients presenting a high level of insight about
their illness.
A high level of insight about the illness can be an indi-
cation for proposing an LAI SGA as a 2nd line treatment.
Table 6 Indications of LAI FGA and LAI SGA according to clinical characteristics of the illness
Schizophrenia Bipolar disorder
1st line LAI FGA or LAI SGA Frequent relapses
Non-adherence (partial/full)
Hazard risk for others
Low insight
Patient preference
Positive depot experienced
1st line Non-adherence (partial/full)
Patient preference
Positive depot experienced
LAI SGA Cognitive deficits Social isolation LAI SGA
2nd line LAI FGA or SGA Positive symptoms 2nd line BD I
Manic polarity
Rapid cycler
Hazard risk for others
Low insight
LAI SGA Negative symptoms
Suicidal risk
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LAI FGA are not recommended in cases of high levels
of insight about the illness.
Bipolar disorder
The preferential choice criteria for an LAI formula-
tion (as 1st line treatment) in bipolar patients are:
– Patients presenting poor adherence with non-
acceptance of a long-term oral treatment.
LAI SGA are recommended as a 1st line treatment (in
monotherapy or in combination).
– Patients wishing for an LAI SGA treatment and/or
having a history of effective treatment with LAI SGA
for bipolar disorder symptoms.
Irrespective of the clinical situation, LAI FGA are
never recommended as maintenance treatment for bipo-
lar disorder.
The experts failed to reach a favorable consensus for the
preferential use of a LAI formulation (as 1st line treatment)
for the following groups. They just specified the preferential
category of LAI (FGA or SGA) for these groups.
– Patient presenting particular clinical characteristics.
Owing to the medications currently available, LAI
SGA are recommended (as 2nd line treatment) in pa-
tients presenting a type I bipolar disorder and/or a pre-
dominant manic polarity and/or rapid cycles.
– Patients presenting a dangerous behavior or a
history of impulsive behavior.
LAI SGA are recommended as 2nd line treatment.
– Patients presenting a low level of insight about
the need for treatment.
LAI SGA are recommended as 2nd line treatment.
Benefit/risk balance for LAI FGA and LAI SGA depending on
the psychiatric disorder
In patients with schizophrenia The assessment of the
benefit/risk ratio for each LAI formulation in the prevent-
ive treatment of psychotic recurrence is presented in
Table 7. The relevant question from the survey with the ex-
perts’ answers are given in Figure 3.
The molecule ranking appears to be directly linked to
the tolerance level for each LAI antipsychotic. LAI SGA
are recommended as 1st line treatment except for olan-
zapine pamoate.
In patients with bipolar disorder Only two LAI SGA
are recommended as 2nd line treatment: risperidone
microsphere and olanzapine pamoate (Table 8). LAI
FGA are contraindicated as maintenance treatment of
bipolar disorder.
Procedures for prescribing and use
Patients stabilized by an antipsychotic treatment
Switch from an oral form antipsychotic (FGA or
SGA) to an LAI form First-line strategy is to start with
the antipsychotic oral form for the length of time re-
quired to obtain an effective dose and good tolerance be-
fore switching to the LAI form.
Note. Only risperidone microspheres have the pharma-
cokinetic characteristics that imperatively require an ini-
tial oral supplement.
The prescription of LAI SGA must be made while tak-
ing into account the pharmacokinetic characteristics of
each product.
The dose of the introduced LAI form will correspond
to the equivalent of the used oral dose (strategy of
choice).
Switch from an LAI antipsychotic (FGA or SGA) to
another LAI antipsychotic First-line strategy is to
introduce the new LAI antipsychotic after the discon-
tinuation of the current LAI FGA or LAI SGA (when
the time since the last injection corresponds to the
interval between 2 injections).
In 2nd line strategy, the switch from the current LAI
FGA or LAI SGA to the new LAI SGA is recommended
directly after having given an oral test dose of the newly
introduced SGA LAI in order to eliminate any
hypersensitivity.
The initial dose for the oral form or for the new LAI
SGA will correspond (if possible) to an equivalent dose
of the previous LAI FGA or LAI SGA (1st line strategy).
Practical procedures for the introduction and for the
injection reminders
In order to help with the acceptance and under-
standing of the benefits of an LAI treatment, it is
Table 7 Benefit/risk ratio for LAI FGA and LAI SGA in
schizophrenia
Prevention of psychotic recurrence
1st line treatment Risperidone LAI
2nd line treatment Olanzapine pamoate
Haloperidol decanoate
Zuclopenthixol decanoate
Flupentixol decanoate
Fluphenazine decanoate
Pipotiazine palmitate
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unanimously recommended by the experts (strategy
of choice) to convey to the patient specific informa-
tion concerning both the advantages and inconve-
niences of the FGA and SGA LAI, which are being
considered, in the framework of shared decision-
making.
During the introduction of the treatment, initiation
of the LAI form is recommended before the end of a
full-time hospitalization for an acute episode (strategy
of choice). Introduction of LAI antipsychotics can
also be considered during outpatient care (as 2nd line
strategy).
The 1st line strategy of performing the injections dur-
ing the maintenance treatment in outpatients is to co-
ordinate the follow-up psychiatric consultations with the
dates of the injections. The injections can also be per-
formed by a nurse in a hospital day care unit or at home
(as 1st line strategy).
Note: these injection procedures are not applicable to
olanzapine pamoate as this treatment requires specific
post-injection monitoring in a hospital.
In order to improve patient compliance, it is recom-
mended that the following reminder techniques are put
in place:
– 1st line strategies, using telephone reminders and
agenda given to the patient (follow-up diary).
– 2nd line strategies, by letter or eventually by text
messages.
The prevention of local complications requires the in-
jections to be performed:
– deep intramuscularly (gluteal or deltoid muscle)
(strategy of choice).
– by changing the injection site each time (as 1st line
strategy).
– by proposing a local transdermal anaesthetic (cream or
patch) before the injection in order to reduce the pain
at the injection site (as 2nd line strategy).
Specific therapeutic strategies according to the psychiatric
disorder or its co-morbidities
Schizophrenia and delusional chronic disorder
Acute psychotic episode with LAI FGA or LAI SGA
treatment
The relevant question from the survey with the experts’
answers are given in Figure 4.
Figure 3 Graphic results of the question about benefit/risk balance for LAI FGA and LAI SGA in schizophrenic patients.
Table 8 Benefit/risk ratio for LAI FGA and LAI SGA in
bipolar disorder
Prevention of manic
recurrence
Prevention of depressive
recurrence
1st-line
treatment
- -
2nd-line
treatment
In monotherapy or in combination
with a mood stabilizer
Always in combination
with a mood stabilizer
Risperidone LAI Risperidone LAI
Olanzapine pamoate Olanzapine pamoate
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- In the acute phase
Several therapeutic adaptations are recommended as 1st
line strategies:
– Optimization of the current LAI antipsychotic.
* either dose optimization of the current LAI FGA or LAI
SGA by increasing the dose while monitoring tolerance.
* or for LAI FGA: reduction of the time between 2
injections.
– Combination of an oral antipsychotic with the
current LAI antipsychotic.
The discontinuation of the current LAI antipsychotic
and the switch to an oral antipsychotic in the acute
phase is only recommended as 2nd line strategy.
- After stabilization of the psychotic episode
It is recommended to continue as maintenance treat-
ment the therapeutic strategy that allowed the reduction
of symptoms and the stabilization of the episode (strat-
egy of choice).
In the case of a switch to an oral antipsychotic treat-
ment during the acute phase, switching to an LAI for-
mulation as maintenance treatment is recommended as
the 1st line strategy.
In the case of the combination of an oral antipsychotic
and an LAI antipsychotic in the acute phase, opti-
mizing the dose of the LAI antipsychotic and pro-
gressively discontinuing the oral antipsychotic while
monitoring the clinical state is recommended as the
1st line strategy.
Residual symptoms with LAI antipsychotics justifying a
reassessment
It is successively recommended:
– in 1st line strategies: to optimize the treatment by
LAI FGA or LAI SGA.
* by dose optimization of the current LAI anti-
psychotic by increasing the dose while monitoring
tolerance.
* or for LAI FGA: by reducing the time between 2
injections.
– in 2nd line strategies.
* either through a combination of an oral antipsychotic
with the current LAI antipsychotic.
* or by changing the current LAI FGA or LAI
SGA for another LAI antipsychotic (preferably a LAI
SGA).
Figure 4 Graphic results of the question about therapeutic strategies during an acute psychotic episode.
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Bipolar disorder
Manic episode with LAI SGA
-In the acute phase
If monotherapy is ongoing, it is successively
recommended:
– in 1st line strategy: to combine the current LAI SGA
with an oral anti-manic mood stabilizer (without rec-
ommendation of a specific medication).
– in 2nd line strategies.
* to optimize the dose of the current LAI SGA by in-
creasing the dose while monitoring tolerance.
* or to discontinue the current LAI SGA and switch to
an oral anti-manic mood stabilizer (without recommen-
dation of a specific medication).
If bitherapy is ongoing (LAI SGA + lithium or anticon-
vulsant), it is successively recommended:
– in 1st line strategy: to optimize the dose of the oral
anti-manic mood stabilizer.
– in 2nd line strategies.
* either to combine the current LAI SGA with another
oral anti-manic mood stabilizer (without recommenda-
tion of a specific medication).
* or to optimize the dose of the current LAI SGA by
increasing the dose while monitoring tolerance.
* or to discontinue the current LAI SGA and switch to
a bitherapy of oral anti-manic mood stabilizers (without
recommendation of a specific medication).
* or to continue the current treatment and combin-
ation with a 2nd oral anti-manic mood stabilizer (without
recommendation of a specific medication).
* or to continue the current treatment and electrocon-
vulsive therapy (ECT) administration.
- After stabilization of the manic episode
It is recommended to continue as maintenance treatment
the therapeutic strategy that allowed the reduction of the
symptoms and the stabilization of the episode (no pre-
cision on the duration) (strategy of choice).
Depressive bipolar episode with LAI SGA
- In the acute phase
If monotherapy is ongoing, it is successively rec-
ommended:
– in 1st line strategy: to combine the current LAI
SGA with an oral mood stabilizer with antidepressant
effect (i.e. lamotrigine, quetiapine, lithium).
– in 2nd line strategies.
* either to optimize the dose of the current LAI SGA
by increasing the dose while monitoring tolerance.
* or to combine the current LAI SGA with an oral
antidepressant or with a series of ECT.
* or to discontinue the current LAI SGA and switch to
an oral mood stabilizer with antidepressant effect.
If bitherapy is ongoing (LAI SGA + antidepressant),
it is successively recommended:
– in 1st line strategies.
* either to optimize the dose of the current oral anti-
depressant by increasing the dose while monitoring
tolerance.
* or to continue the combination of a LAI SGA with
an antidepressant and combination with an oral mood
stabilizer with antidepressant effect.
– in 2nd line strategies.
* either to combine another oral antipsychotic with
the current LAI SGA.
* or to optimize the dose of the current LAI SGA by
increasing the dose while monitoring tolerance.
* or to discontinue the current LAI SGA and switch to a
bitherapy of oral mood stabilizers and oral antidepressant.
* or to continue the current treatment and ECT
administration.
- After stabilization of the depressive episode
In the 1st line strategy, it is recommended to continue as
maintenance treatment the therapeutic strategy that
allowed the reduction of symptoms and the stabilization
of the clinical state (no precision of the duration).
In the 2nd line strategy, in the case of the combination
of an oral antidepressant with an LAI SGA in the acute
phase, it is recommended to optimize the dose of the
LAI SGA and to progressively discontinue the oral anti-
depressant, depending on the clinical state.
Psychiatric co-morbidities associated with a schizophrenic
or bipolar disorder with an LAI antipsychotic
Manifestations of anxiety (structured or non-structured)
It is recommended in 1st line treatment to associate an
oral benzodiazepine, and in 2nd-line treatment to com-
bine an antidepressant (as first-line treatment, an SSRI
or SNRI).
Addiction to a psychoactive substance (alcohol, opiates…)
Treatment by LAI SGA or LAI FGA can be continued.
The prescription of opiate substitutes (buprenorphine or
methadone) (1st line strategies) or disulfiram, acamprosate
or naltrexone (2nd line strategies) depending on the addic-
tion, is possible with LAI antipsychotics.
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Procedures for follow-up and monitoring
Pre-therapeutic LAI antipsychotic summary
As 1st line strategies, it is recommended to systematically
search for the following clinical elements:
– Personal and family medical history (diabetes,
dyslipidaemia).
– Healthy lifestyle (eating habits, physical activity,
substance use, smoking).
– Weight, Body Mass Index calculation, umbilical
circumference.
– Blood pressure.
It is recommended to perform the following paraclin-
ical checkups:
 1st line paraclinical exams:
– Complete blood count, blood electrolyte (+ urea,
creatinine, fasting glucose).
– Liver function tests.
– Lipid profile.
– Beta hCG.
– Electrocardiogram.
 Paraclinical exams depending on the clinical state of
patient (as 2nd line):
– Thyroid function test.
– Prolactinaemia.
– Electroencephalogram.
All the experts recommended informing the patient
and the family of the risks of adverse event occurrence
(metabolic, neurological…) as well as providing hygiene
and diet advice (balanced diet, regular physical activity,
reduction or help in stopping substance use…) (strategy
of choice).
Monitoring procedures
Clinical and paraclinical monitoring of LAI antipsy-
chotics is the same as for oral antipsychotics
The specific monitoring frequency will depend on the
risk factors found in the patient and on the clinical
signs that appear during the treatment as well (1st-line
strategies).
Specific populations
Women during pregnancy
In the case of planned pregnancy in a woman treated
with LAI antipsychotic
The experts failed to reach a favorable consensus for
1st-line strategies in this clinical situation. As a 2nd line
strategy, it is recommended to discontinue the current
LAI antipsychotic and switch to the oral form (at the
minimum effective dose).
In the case of discovering a pregnancy
In the 1st/2nd/3rd trimester: The experts failed to reach a
consensus for 1st line strategies. As 2nd line strategies
continuation of the LAI antipsychotic or switching to an
oral form (FGA or SGA at the minimum effective dose)
is recommended.
Elderly patients
The relevant question from the survey with the experts’
answers are given in Figure 5.
In elderly patients over 65 years, the use of an LAI
antipsychotic is possible. Certain precautions are recom-
mended as 1st line strategies when prescribing an LAI
treatment:
– Dosage adjustment according to weight, liver or
renal function tests.
– A longer titration than in adults with a lower
“target” dose.
– Close medical follow-up (strategy of choice).
– Closer tolerance monitoring than in adults (strategy
of choice).
– Prescription only by a psychiatrist.
Subjects in precarious situations
In subjects in a precarious situation, the use of an LAI
SGA is recommended as 1st line treatment (LAI FGA as
2nd line treatment).
Subjects incarcerated in prison
With incarcerated patients, the use of an LAI antipsychotic
can be considered. This prescription does not differ accord-
ing to the length or the place of incarceration.
The psychiatric indications are the same as for the
non-incarcerated population, with the difference being
that LAI SGA appears as the treatment of choice for
schizophrenic and delusional disorders.
The presence of the following clinical characteristics
(aggressiveness, previous history of risk for others) guides
the therapeutic choice in favour of an LAI FGA or an
LAI SGA in schizophrenic disorders or towards an LAI
SGA in bipolar disorders (1st line strategies).
Discussion
The main interest of our work is to help clinicians make
the choice of using an LAI antipsychotic in specific clin-
ical circumstances, using the methodology of consensus-
based guidelines (CBG).
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Evidence-based guidelines vs. consensus-based guidelines
Most guidelines for the treatment of psychiatric disor-
ders are evidence-based guidelines (EBG) [11,20]. How-
ever, recommendations cannot be established if there is
no evidence available, in which case, CBG methodology
can be used. The French National Health agency [19]
recommends the Formal Consensus method when two
of the following conditions are met:
– No or insufficient level of evidence addressing the
question.
– Possibility to decline the topic in easily identifiable
clinical situations.
– Need to identify and select the strategies deemed
appropriate by an independent panel from amongst
several alternative options.
This method is very close to the Expert Consensus
Guidelines methodology and has been applied to a var-
iety of psychiatric disorders [4,21-27].
Combining EBG and CBG methodologies may help
clinicians to have a real evidence-based clinical
practice, including both clinical expertise and scien-
tific evidence [20].
In the field of LAI antipsychotic use and management,
CBG methodology appears to be particularly appropriate.
Evidence concerning LAI antipsychotic efficacy and toler-
ability exists but it is lacking in many areas (i.e. indications
or preferential patient profiles, a ranking system between
LAI antipsychotics, the introduction stage, process for
switching, medication management, specific populations…).
CBGs allow the clinician to be led by recommendations
that bear a closer relation to the characteristics of the pa-
tients followed in clinical practice than to the restrictive
inclusion criteria of randomized-controlled trials [20].
Indications of LAI antipsychotics
According to our experts’ panel, LAI antipsychotics are
recommended as first-line treatment in various psychi-
atric disorders:
– Schizophrenia.
– Schizoaffective disorder.
– Delusional disorder.
Figure 5 Graphic results of the question about therapeutic strategies in elderly patients.
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But also as second-line treatment in:
– Bipolar disorder.
– Personality disorder.
If their use in schizophrenia is common and supported
by evidence [5-7,28], their use in bipolar disorder is less
obvious. Nevertheless, several placebo-controlled relapse
prevention studies have shown the efficacy of risperi-
done microsphere as a monotherapy or as an adjunctive
therapy to lithium or valproate in bipolar I patients [29].
In September 2011, and based on this data, the Food
and Drug Administration Agency approved risperidone
microsphere as a long-term treatment for bipolar I dis-
order. Scientific literature is currently limited to risperi-
done microsphere but the development of new drugs
should allow further studies with LAI SGA as mainten-
ance treatment for bipolar disorder.
The use of LAI antipsychotics in other indications
(schizoaffective disorder, delusional disorder, personality
disorder) is not based on evidence for these populations
but is instead based on the clinical experience of our ex-
perts’ panel. If scientific evidence is required then the
sharing of this experience can be considered as a real
support for the clinical use of these compounds.
Use of LAI antipsychotics during the different phases of
the illness
In recent years the interest of using LAI SGA in the
early phase of schizophrenia has increased because the
duration of untreated psychosis is associated with the
prognosis of the illness [30]. Recent studies have under-
lined the fact that their use, as early as the first psychotic
episode, offers many advantages in terms of efficacy,
tolerance and improved adherence [31-33]. The available
literature presents a weak level of evidence (open
label, post-hoc analysis, and small sample) and placebo-
controlled studies are needed. The formalized consensus
of our experts’ panel is consistent with these preliminary
results and recommends LAI SGA after the first schizo-
phrenic episode.
The extension of this data to the first manic episode
in bipolar disorder could be assumed but, to date, no
data has emerged that compares the effect of the early
introduction of oral or LAI antipsychotics on the course
of the illness. This is probably the reason why the ex-
perts’ panel did not recommend LAI SGA in the early
course of bipolar disorder as a maintenance treatment.
What is the specific clinical profile of patients using LAI
antipsychotics in clinical practice?
Our experts’ panel considers that LAI antipsychotics
should be used with any patients with schizophrenia
for whom maintenance antipsychotic treatment is
indicated. This is consistent with the results of a survey
conducted among psychiatrists from Europe, Middle-East
and Africa, in which clinicians considered switching to or
adding an LAI antipsychotic as the preferential pharmaco-
logical approach for addressing adherence problems [34].
LAI antipsychotics have long been viewed as a treat-
ment that could only be used for a small subgroup of pa-
tients with non-compliance, frequent relapses or who
pose a risk to others. A cluster analysis of French and
German studies, surveying psychiatrists about patient at-
tributes that potentially influence their qualification for
depot treatment, identified two clusters of patients
[35,36]. Cluster I corresponded to the classical patient
profile in whom depot forms are used (past history of re-
lapse and poor compliance with oral forms). Cluster II
was more unexpected and included patients with high
levels of insight and of therapeutic alliance. The useful-
ness of depot formulations compared with oral treat-
ment in terms of relapse prevention is not demonstrated
in this population [35,36]. However, even limited gaps of
treatment with oral formulation (11–30 days a year) is
enough to increase the risk of relapse by 2.81 in patients
with schizophrenia [37]. The identification of the two
clusters, replicated in numerous countries, is consistent
with the recommendation of our experts’ panel.
Considering the risks associated with non-compliance
in bipolar patients [38,39], the experts’ panel recom-
mends LAI antipsychotics as a second-line treatment in
bipolar disorder.
LAI FGA vs LAI SGA
If the superiority of LAI antipsychotics versus placebo,
in terms of relapse prevention, has been demonstrated
[5,28] for schizophrenia, no study compares the LAI
SGA versus LAI FGA.
We can only extrapolate the results from studies on oral
antipsychotics. Some individual oral SGA (amisulpride, clo-
zapine, olanzapine, risperidone) were better in overall effi-
cacy in patients with schizophrenia than oral FGA [17].
Other oral SGA were no more effective, even for negative
symptoms. However, a meta-analysis which considered
all oral SGA as a single group demonstrated that they were
associated with fewer relapses, less treatment failures
and fewer hospitalizations in the long-term treatment of
schizophrenia [40]. Oral SGA induced fewer extrapyramidal
side effects than oral FGA but some SGA induced more
weight gain or metabolic side effects than oral FGA [41,42].
Tolerance profiles of oral SGA are more mixed and require
the characteristics of each molecule to be taken into
account on an individual basis.
In a one-year observational study including 1859
patients diagnosed with schizophrenia, an adjusted
Poisson regression analysis showed that the use of ris-
peridone microsphere was associated with a lower rate
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of hospitalization compared to the use of other LAI
FGA [43].
So, with no evidence available, the experts’ panel rec-
ommended that the clinician’s decision-making process
takes into account the benefit/risk balance and prioritizes
LAI SGA (except for olanzapine pamoate, due probably to
the risk of post-injection syndrome [44]) over LAI FGA,
according to patient tolerance.
Use of LAI antipsychotics in clinical practice guidelines
The management of LAI antipsychotics in clinical prac-
tice can sometimes be complex for clinicians and there
are limited data or recommendations in the literature.
Our guidelines try to propose practical recommenda-
tions to facilitate the introduction, switching and man-
agement of LAI antipsychotics in the different phases of
schizophrenia or bipolar disorder.
Indeed, the current EBG for biological treatment of
schizophrenia and bipolar disorder [8-10,45-53] propose
few recommendations concerning LAI antipsychotics.
Most of them recommend the use of LAI antipsy-
chotics only for patients with non-adherence, frequent
recurrence or who prefer this formulation. The condi-
tions of use and management are not, or are only briefly,
described. LAI antipsychotics are presented separately
from the oral medication strategies (except for the
CANMAT guidelines in bipolar disorder).
The main reasons given in explanation for the limited
number of recommendations regarding LAI antipsy-
chotics are related to the lack of long-term studies and
the lack of high-quality evidence comparing LAI SGA to
oral SGA. Perhaps the follow-up period, lasting a year or
less, may have been too short to reveal the longer-term
benefits of depot treatment versus oral form [9,46].
However, in our opinion, the current criteria for level
of evidence are probably not adapted to the studies
dealing with LAI antipsychotics. Indeed, randomized-
controlled trials have a major selection bias and cannot
assess the potential adherence benefits of LAI formula-
tions (non-compliant patients do not participate in a
trial and those who accept to be included are the most
compliant). Therefore, it can be difficult to demonstrate
the benefit of LAI antipsychotics compared with oral
antipsychotics. Future studies with LAI antipsychotics
should combine the strengths of the different study
designs (randomized-controlled studies, mirror-image
studies or cohort studies).
In addition to these EBG, there are some CBG focus-
ing on the use and management of LAI formulations for
the treatment of schizophrenia [4,27,54-57].
The first guidelines, published in 1998, already recom-
mended that LAI FGA should be considered for “any
patients with schizophrenia for whom long-term treatment
is indicated” [54]. However, with the emergence in the
years that followed of oral SGA, which are better tolerated
compared to FGA, most of the guidelines have been in
favour of the use of the oral formulation. Since the market
authorization (2002) of the first LAI SGA (risperidone
microsphere), two other specific guidelines concerning
LAI antipsychotics [27,57] have been proposed. These
guidelines recommended LAI SGA as first-line treatment
for patients who request the long-acting formulations.
Their use after the first schizophrenic episode or for
patients who are stable with oral antipsychotics has been
discussed.
In 2009, Velligan et al. published expert consensus
guidelines about adherence problems in patients with
serious mental illness [4]. Use of LAI antipsychotics was
a personal choice for patients with frequent relapses
associated with non-adherence, relapses because they
stopped taking the medication, or because they expressed a
preference for the LAI formulation.
The Association des médecins psychiatres du Québec
(AMPQ) has also recently developed guidelines concern-
ing LAI antipsychotics with a decisional algorithm,
which places the depot formulation in every step of
treatment as soon as possible [56].
Conclusion
The evolution of the therapeutic arsenal for schizophre-
nia and bipolar disorder, with the development of LAI
FGA, then oral SGA, and finally LAI SGA, probably ex-
plain the difficulties in changing the prescribing practice
for clinicians. Some clinicians consider LAI antipsy-
chotics to be coercive, stigmatizing, unacceptable for
patients or impossible to stop immediately when side ef-
fects occur [4,13,15]. The negative attitudes of psychia-
trists toward LAI antipsychotics mean they require a
high level of evidence that depot formulation is clearly
superior as a maintenance treatment to oral antipsy-
chotics [58]. Negative beliefs towards depot formulations
could be decreased using, as is recommended, shared
decision-making and minimizing the experience of pa-
tient coercion. The current and future availability of a
larger number of LAI SGA (aripiprazole, paliperidone,
olanzapine, risperidone) should allow the clinicians to
embrace depot treatments more easily.
If the interest in LAI treatments has been shown in
terms of a decreased risk of relapse in patients with
schizophrenia, studies are still required that are adapted,
from a methodological point of view, to the assessment
of LAI antipsychotics, particularly after the first psych-
otic episode.
In an evidence-based clinical approach, psychiatrists
should be systematically offering to all patients that re-
quire long-term antipsychotic treatment, through shared
decision-making, an LAI antipsychotic as a first-line
treatment (key points are summarized in Appendix 3).
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Appendix 3: key points
– 1. Long-acting injectable (LAI) antipsychotics are indi-
cated in patients with schizophrenia, schizoaffective
disorder, delusional disorder and bipolar disorder.
– 2. LAI second-generation antipsychotics (SGA)
are recommended as maintenance treatment
after the first episode of schizophrenia. LAI first-
generation antipsychotics (FGA) (depot neuroleptics)
are not recommended in the early course of schizo-
phrenia and must be avoided in bipolar disorder.
– 3. LAI antipsychotics have long been viewed as a
treatment that could only be used for a small
subgroup of patients with non-compliance, fre-
quent relapses or who pose a risk to others. The
panel considers that LAI antipsychotics should be
considered and systematically proposed to any
patients for whom maintenance antipsychotic
treatment is indicated.
– 4. According to their efficacy and tolerability:
* LAI SGA are recommended as first line and LAI
FGA as second line in the maintenance treatment of
schizophrenia.
*LAI SGA are recommended as second line as a
monotherapy to prevent manic recurrence or in combin-
ation with a mood stabilizer to prevent depressive recur-
rence in the maintenance treatment of bipolar disorder.
– 5. In order to improve the acceptance and
understanding of the benefits of an LAI antipsychotic,
it is recommended to deliver to each patient specific
information concerning the advantages and incon-
veniences of the LAI formulation, in the framework of
shared decision-making.
– 6. Process for switching to LAI antipsychotic. Two
main situations are identified:
* Switch from an oral antipsychotic:
* Prescribe the oral formulation of the antipsychotic to
establish tolerability/efficacy.
* Use an initial dose of the LAI antipsychotic equiva-
lent to oral form.
* Switch from another LAI antipsychotic:
* Use several test doses of the oral formulation of the
LAI antipsychotic if patient has never taken this medica-
tion previously (to rule out hypersensitivity).
* Introduce the new LAI antipsychotic at the sched-
uled period of the next injection.
* Use an initial dose of the LAI antipsychotic equiva-
lent to the previous LAI.
– 7. Medication management:
* Reminders of injection date must be used to improve
compliance.
* First line: phone call and diary.
* Second line: letter or text message.
* Coordinate the dates of medical consultations
with the scheduled dates of LAI antipsychotic injections.
* Respect the prevention of local complications when
administrating LAI:
* Administered by competent/training professional
(nurse, psychiatrist, GP),.
* Check the length of needle and penetrate the deep
muscle tissue,.
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* Select the injection site according to patient
preference,.
* Propose systematically a local anaesthetic to reduce
pain at the injection site.
* The change of the injection site, for each injection,
can be evoked.
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LAI: Long-acting injectable; ECT: Electroconvulsive therapy; CBG: Consensus-
based guidelines; EBG: Evidence-based guidelines.
Competing interests
Pr Llorca, Pr Courtet and Dr Abbar have received grants and served as
consultant or speaker for the following entities: AstraZeneca, Bristol-Myers
Squibb, El Lilly, Janssen-Cilag, Lundbeck, Otsuka, Sanofi-Aventis and Servier.
Dr Samalin has received grants and served as speaker for the following
entities: AstraZeneca, Bristol-Myers Squibb, El Lilly, Lundbeck, Otsuka and
Sanofi-Aventis. Dr Guillaume has no conflict of interest.
Authors’ contributions
PML and LS have been involved in drafting the manuscript. SL has made
substantial contributions to the acquisition and analysis of data. All authors
have made substantial contributions to the conception, design and
interpretation of data, have been involved in revising the manuscript
critically for important intellectual content and have given final approval of
the version to be published.
Acknowledgements
This work was supported by grants from the French Association for
Biological Psychiatry and Neuropsychopharmacology (AFPBN).
Author details
1CHU Clermont-Ferrand, EA 7280, Clermont-Ferrand University, Clermont-
Ferrand, France. 2Department of Adult Psychiatry, CHU Caremeau, Nîmes,
France. 3CHRU Montpellier, INSERM U1061, Montpellier University,
Montpellier, France. 4Sylia-Stat, Paris, Bourg-la-Reine, France.
Received: 16 August 2013 Accepted: 12 December 2013
Published: 20 December 2013
References
1. Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP:
Strategies for addressing adherence problems in patients with serious and
persistent mental illness: recommendations from the expert consensus
guidelines. J Psychiatr Pract 2010, 16:306–324.
2. Kreyenbuhl J, Slade EP, Medoff DR, Brown CH, Ehrenreich B, Afful J, Dixon LB:
Time to discontinuation of first- and second-generation antipsychotic
medications in the treatment of schizophrenia. Schizophr Res 2011,
131:127–132.
3. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV: Prevalence of and
risk factors for medication nonadherence in patients with schizophrenia:
a comprehensive review of recent literature. J Clin Psychiatry 2002,
63:892–909.
4. Velligan DI, Weiden PJ, Sajatovic M, Scott J, Carpenter D, Ross R, Docherty JP:
The expert consensus guideline series: adherence problems in
patients with serious and persistent mental illness. J Clin Psychiatry
2009, 70(Suppl 4):1–46. quiz 47–48.
5. Adams CE, Fenton MK, Quraishi S, David AS: Systematic meta-review of
depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry
2001, 179:290–299.
6. Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M,
Borenstein M, Kane JM, Correll CU: Long-acting injectable vs oral
antipsychotics for relapse prevention in schizophrenia: a meta-analysis
of randomized trials. Schizophr Bull 2013.
7. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S: Oral versus
depot antipsychotic drugs for schizophrenia – a critical systematic
review and meta-analysis of randomised long-term trials. Schizophr Res
2011, 127:83–92.
8. Canadian Psychiatric Association: Clinical practice guidelines. Treatment of
schizophrenia. Can J Psychiatry 2005, 50:7S–57S.
9. Schizophrenia: Core interventions in the treatment and management of
schizophrenia in primary and secondary care (update). [http://www.ncbi.
nlm.nih.gov/pubmed/20704054]
10. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA,
Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W: The 2009
schizophrenia PORT psychopharmacological treatment
recommendations and summary statements. Schizophr Bull 2010,
36:71–93.
11. Takeuchi H, Suzuki T, Uchida H, Watanabe K, Mimura M: Antipsychotic
treatment for schizophrenia in the maintenance phase: a systematic
review of the guidelines and algorithms. Schizophr Res 2012, 134:219–225.
12. Barnes TR, Shingleton-Smith A, Paton C: Antipsychotic long-acting
injections: prescribing practice in the UK. Br J Psychiatry Suppl 2009,
52:S37–S42.
13. Patel MX, David A: Why aren’t depot antipsychotics prescribed more
often and what can be done about it? Adv Psychiatr Treat 2011, 11:203–213.
14. Fourrier A, Gasquet I, Allicar MP, Bouhassira M, Lepine JP, Begaud B:
Patterns of neuroleptic drug prescription: a national cross-sectional
survey of a random sample of French psychiatrists. Br J Clin
Pharmacol 2000, 49:80–86.
15. Heres S, Hamann J, Kissling W, Leucht S: Attitudes of psychiatrists
toward antipsychotic depot medication. J Clin Psychiatry 2006,
67:1948–1953.
16. Haute Autorité de Santé: Guide d’analyse de la littérature et gradation
des recommandations. [http://www.has-sante.fr/portail/upload/docs/
application/pdf/analiterat.pdf]
17. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM: Second-generation
versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.
Lancet 2009, 373:31–41.
18. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F,
Asenjo Lobos C, Schwarz S, Davis JM: A meta-analysis of head-to-head
comparisons of second-generation antipsychotics in the treatment of
schizophrenia. Am J Psychiatry 2009, 166:152–163.
19. Haute Autorité de Santé: Elaboration de recommandations de bonne
pratique. Méthode “Recommandations par consensus formalisé”. 2011:
[http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-11/
guide_methodologique_cf_40_pages_2011-11-03_15-40-2_278.pdf]
20. Samalin L, Guillarma S, Courtet P, Abbar M, Lancrenon S, Llorca PM:
Methodological differences between pharmacological treatment
guidelines for bipolar disorder: what to do for the clinicians? Compr
Psychiatry 2013, 54:309–320.
21. Llorca PM, Courtet P, Martin P, Abbar M, Gay C, Meynard JA, Bayle F, Hamon M,
Lancon C, Thibaut F, Thomas P, Lancrenon S, Guillaume S, Samalin L: Screening
and management of bipolar disorders: methodology. Encephale 2010,
36(Suppl 4):S76–S85.
22. Llorca PM, Courtet P, Martin P, Abbar M, Gay C, Meynard JA, Bayle F,
Hammon M, Lancon C, Thibaut F, Thomas P, Lancrenon S, Guillaume S,
Samalin L: Screening and management of bipolar disorders: results.
Encephale 2010, 36(Suppl 4):S86–S102.
23. Alexopoulos GS, Jeste DV, Chung H, Carpenter D, Ross R, Docherty JP: The
expert consensus guideline series. Treatment of dementia and its
behavioral disturbances. Introduction: methods, commentary, and
summary. Postgrad Med 2005, Spec No.:6–22.
24. Alexopoulos GS, Katz IR, Reynolds CF 3rd, Carpenter D, Docherty JP:
The expert consensus guideline series. Pharmacotherapy of depressive
disorders in older patients. Postgrad Med 2001, Spec No
Pharmacotherapy:1–86.
25. Allen MH, Currier GW, Carpenter D, Ross RW, Docherty JP: The expert
consensus guideline series. Treatment of behavioral emergencies 2005.
J Psychiatr Pract 2005, 11(Suppl 1):5–108. quiz 110–102.
26. Kahn DA, Sachs GS, Printz DJ, Carpenter D, Docherty JP, Ross R: Medication
treatment of bipolar disorder 2000: a summary of the expert consensus
guidelines. J Psychiatr Pract 2000, 6:197–211.
27. Kane JM, Leucht S, Carpenter D, Docherty JP: The expert consensus
guideline series. Optimizing pharmacologic treatment of psychotic
disorders. Introduction: methods, commentary, and summary. J Clin
Psychiatry 2003, 64(Suppl 12):5–19.
28. Fleischhacker WW: Second-generation antipsychotic long-acting injections:
systematic review. Br J Psychiatry Suppl 2009, 52:S29–S36.
Llorca et al. BMC Psychiatry 2013, 13:340 Page 16 of 17
http://www.biomedcentral.com/1471-244X/13/340
29. Samalin L, Nourry A, Charpeaud T, Llorca P: What is the evidence for the use of
second-generation antipsychotic long-acting injectables as maintenance
treatment in bipolar disorder?. Nord J Psychiatry 2013.
30. Lambert M, De Marinis T, Pfeil J, Naber D, Schreiner A: Establishing
remission and good clinical functioning in schizophrenia: predictors of
best outcome with long-term risperidone long-acting injectable treatment.
Eur Psychiatry 2010, 25:220–229.
31. Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J: Oral
versus injectable antipsychotic treatment in early psychosis: post hoc
comparison of two studies. Clin Ther 2008, 30:2378–2386.
32. Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J:
Remission in patients with first-episode schizophrenia receiving assured
antipsychotic medication: a study with risperidone long-acting injection.
Int Clin Psychopharmacol 2008, 23:325–331.
33. Kim B, Lee SH, Choi TK, Suh S, Kim YW, Lee E, Yook KH: Effectiveness of
risperidone long-acting injection in first-episode schizophrenia: in naturalistic
setting. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1231–1235.
34. Olivares JM, Alptekin K, Azorin JM, Canas F, Dubois V, Emsley R, Gorwood P,
Haddad PM, Naber D, Papageorgiou G, Roca M, Thomas P, Martinez G,
Schreiner A: Psychiatrists’ awareness of adherence to antipsychotic
medication in patients with schizophrenia: results from a survey
conducted across Europe, the Middle East, and Africa. Patient Prefer
Adherence 2013, 7:121–132.
35. Samalin L, Charpeaud T, Blanc O, Heres S, Llorca P: Clinicians’ attitudes
toward the use of long-acting injectable antipsychotics. J Nerv Ment Dis
2013, 201(7):553–559.
36. Heres S, Hamann J, Mendel R, Wickelmaier F, Pajonk FG, Leucht S, Kissling W:
Identifying the profile of optimal candidates for antipsychotic
depot therapy A cluster analysis. Prog Neuropsychopharmacol Biol
Psychiatry 2008, 32:1987–1993.
37. Weiden PJ, Kozma C, Grogg A, Locklear J: Partial compliance and risk of
rehospitalization among California Medicaid patients with schizophrenia.
Psychiatr Serv 2004, 55:886–891.
38. Gutierrez-Rojas L, Jurado D, Martinez-Ortega JM, Gurpegui M: Poor adherence
to treatment associated with a high recurrence in a bipolar disorder
outpatient sample. J Affect Disord 2010, 127:77–83.
39. Hassan M, Lage MJ: Risk of rehospitalization among bipolar disorder
patients who are nonadherent to antipsychotic therapy after hospital
discharge. Am J Health Syst Pharm 2009, 66:358–365.
40. Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU: Relapse
prevention in schizophrenia: a systematic review and meta-analysis of
second-generation antipsychotics versus first-generation antipsychotics.
Mol Psychiatry 2013, 18:53–66.
41. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W,
Davis JM, Leucht S: Second-generation antipsychotic drugs and
extrapyramidal side effects: a systematic review and meta-analysis of
head-to-head comparisons. Schizophr Bull 2012, 38:167–177.
42. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA,
Kissling W, Davis JM, Leucht S: Head-to-head comparisons of metabolic
side effects of second generation antipsychotics in the treatment of
schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010,
123:225–233.
43. Grimaldi-Bensouda L, Rouillon F, Astruc B, Rossignol M, Benichou J, Falissard B,
Limosin F, Beaufils B, Vaiva G, Verdoux H, et al: Does long-acting injectable
risperidone make a difference to the real-life treatment of schizophrenia?
Results of the Cohort for the General Study of Schizophrenia (CGS). Schizophr
Res 2012, 134:187–194.
44. Detke HC, McDonnell DP, Brunner E, Zhao F, Sorsaburu S, Stefaniak VJ,
Corya SA: Post-injection delirium/sedation syndrome in patients with
schizophrenia treated with olanzapine long-acting injection. I: analysis of
cases. BMC Psychiatry 2010, 10:43.
45. Barnes TR: Evidence-based guidelines for the pharmacological treatment
of schizophrenia: recommendations from the British Association for
Psychopharmacology. J Psychopharmacol 2011, 25:567–620.
46. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F,
Moller HJ: World Federation of Societies of Biological Psychiatry (WFSBP)
guidelines for biological treatment of schizophrenia, part 2: update 2012
on the long-term treatment of schizophrenia and management of
antipsychotic-induced side effects. World J Biol Psychiatry 2013, 14:2–44.
47. Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML,
Essock SM, Finnerty M, Marder SR, Miller DD, McEvoy JP, Robinson DG,
Schooler NR, Shon SP, Stroup TS, Miller AL: The Texas Medication
Algorithm Project antipsychotic algorithm for schizophrenia: 2006
update. J Clin Psychiatry 2007, 68:1751–1762.
48. NICE: National Institute for Health and Clinical Excellence: The management
of bipolar disorder in adults, children and adolescents, in primary and
secondary care. Alden Press UK. edn. London: The British Psychological
Society and the Royal College of Psychiatrists; 2006.
49. Goodwin GM: Evidence-based guidelines for treating bipolar disorder:
revised second edition – recommendations from the British Association
for Psychopharmacology. J Psychopharmacol 2009, 23:346–388.
50. Malhi GS, Adams D, Lampe L, Paton M, O’Connor N, Newton LA, Walter G,
Taylor A, Porter R, Mulder RT, Berk M: Clinical practice recommendations
for bipolar disorder. Acta Psychiatr Scand Suppl 2009, 439:27–46.
51. Frye MA, Ha K, Kanba S, Kato T, McElroy SL, Ozerdem A, Vazquez G, Vieta E:
International consensus group on depression prevention in bipolar
disorder. J Clin Psychiatry 2011, 72:1295–1310.
52. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M,
O’Donovan C, Macqueen G, McIntyre RS, Sharma V, Ravindran A, Young LT,
Milev R, Bond DJ, Frey BN, Goldstein BI, Lafer B, Birmaher B, Ha K, Nolen WA,
Berk M: Canadian Network for Mood and Anxiety Treatments (CANMAT)
and International Society for Bipolar Disorders (ISBD) collaborative
update of CANMAT guidelines for the management of patients with
bipolar disorder: update 2013. Bipolar Disord 2013, 15:1–44.
53. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, Kasper S:
The World Federation of Societies of Biological Psychiatry (WFSBP)
guidelines for the biological treatment of bipolar disorders: update 2012
on the long-term treatment of bipolar disorder. World J Biol Psychiatry
2013, 14:154–219.
54. Kane JM, Aguglia E, Altamura AC, Ayuso Gutierrez JL, Brunello N,
Fleischhacker WW, Gaebel W, Gerlach J, Guelfi JD, Kissling W, Lapierre YD,
Lindström E, Mendlewicz J, Racagni G, Carulla LS, Schooler NR: Guidelines
for depot antipsychotic treatment in schizophrenia. European
Neuropsychopharmacology Consensus Conference in Siena, Italy.
Eur Neuropsychopharmacol 1998, 8:55–66.
55. Kane JM, Garcia-Ribera C: Clinical guideline recommendations for anti-
psychotic long-acting injections. Br J Psychiatry Suppl 2009, 52:S63–S67.
56. Stip E, Abdel-Baki A, Bloom D, Grignon S, Roy MA: Long-acting injectable
antipsychotics: an expert opinion from the Association des Médecins
Psychiatres du Quebec. Can J Psychiatry 2011, 56:367–376.
57. Keith SJ, Kane JM, Turner M, Conley RR, Nasrallah HA: Academic highlights:
guidelines for the use of long-acting injectable atypical antipsychotics.
J Clin Psychiatry 2004, 65:120–131.
58. Hamann J, Mendel R, Heres S, Leucht S, Kissling W: How much more
effective do depot antipsychotics have to be compared to oral
antipsychotics before they are prescribed? Eur Neuropsychopharmacol
2010, 20:276–279.
doi:10.1186/1471-244X-13-340
Cite this article as: Llorca et al.: Guidelines for the use and management
of long-acting injectable antipsychotics in serious mental illness. BMC
Psychiatry 2013 13:340.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Llorca et al. BMC Psychiatry 2013, 13:340 Page 17 of 17
http://www.biomedcentral.com/1471-244X/13/340
